Elaine D. Sun - 17 Mar 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Director
Signature: /s/ Kyle Nelson, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 17 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 19 Mar 2025, 16:27:16 UTC
Previous filing: 19 Mar 2025
Next filing: 13 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+36,549		$0.000000	36,549	17 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+73,099		$0.000000	73,099	17 Mar 2025	Class A Common Stock	73,099	$6.84	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
F2	Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.